Biomarin Pharmaceutical (BMRN) Com Stk USD0.001

Sell:$57.18Buy:$57.20$0.87 (1.55%)

NASDAQ:0.94%
Market closed | Prices delayed by at least 15 minutes
Sell:$57.18
Buy:$57.20
Change:$0.87 (1.55%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$57.18
Buy:$57.20
Change:$0.87 (1.55%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

Key people

Alexander Hardy
President, Chief Executive Officer, Director
Brian R. Mueller
Chief Financial Officer, Executive Vice President
C. Greg Guyer
Executive Vice President and Chief Technical Officer
G. Eric Davis
Executive Vice President, Secretary, Chief Legal Officer
Gregory R Friberg
Executive Vice President, Chief Research & Development Officer
Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Erin Burkhart
Group Vice President, Chief Accounting Officer
James H. Sabry
Chief Business Officer
Richard A. Meier
Non-Executive Independent Chairman of the Board
Elizabeth Mckey Anderson
Independent Director
Barbara W. Bodem
Independent Director
Athena M. Countouriotis
Independent Director
Willard H. Dere
Independent Director
Click to see more

Key facts

  • EPIC
    BMRN
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US09061G1013
  • Market cap
    $10.54bn
  • Employees
    3,040
  • Shares in issue
    191.78m
  • Exchange
    NASDAQ
  • Index
    S&P 400 Mid Cap, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.